These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9365500)

  • 1. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
    Monks A; Scudiero DA; Johnson GS; Paull KD; Sausville EA
    Anticancer Drug Des; 1997 Oct; 12(7):533-41. PubMed ID: 9365500
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antitumor drug screening at the National Cancer Institute, U.S.A].
    Tsuruo T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2809-15. PubMed ID: 3310904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on NCI in vitro drug screen utilities.
    Holbeck SL
    Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Realistic rodents? Debate grows over new mouse models of cancer.
    Garber K
    J Natl Cancer Inst; 2006 Sep; 98(17):1176-8. PubMed ID: 16954466
    [No Abstract]   [Full Text] [Related]  

  • 6. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
    Newell DR
    Br J Cancer; 2001 May; 84(10):1289-90. PubMed ID: 11355935
    [No Abstract]   [Full Text] [Related]  

  • 7. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
    Huang R; Wallqvist A; Thanki N; Covell DG
    Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NCI Developmental Therapeutics Program.
    Collins JM
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New approaches in experimental cancerology: in search of therapeutic models].
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
    Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
    [No Abstract]   [Full Text] [Related]  

  • 11. Mining the NCI screening database: explorations of agents involved in cell cycle regulation.
    Wallqvist A; Monks A; Rabow AA; Thanki N; Shoemaker RH; Covell DG
    Prog Cell Cycle Res; 2003; 5():173-9. PubMed ID: 14593711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 13. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R; Morton C; Houghton PJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
    Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
    Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
    Huang R; Wallqvist A; Covell DG
    J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen.
    Gunnarsdottir S; Elfarra AA
    Drug Metab Dispos; 2004 Mar; 32(3):321-7. PubMed ID: 14977866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen.
    Huang R; Wallqvist A; Covell DG
    Genomics; 2006 Mar; 87(3):315-28. PubMed ID: 16386875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intellectual property. DuPont ups ante on use of Harvard's OncoMouse.
    Marshall E
    Science; 2002 May; 296(5571):1212. PubMed ID: 12016275
    [No Abstract]   [Full Text] [Related]  

  • 19. The hollow fibre model in cancer drug screening: the NCI experience.
    Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA
    Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
    Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.